Your session is about to expire
← Back to Search
Alpelisib + Sacituzumab Govitecan for Breast Cancer (ASSET Trial)
ASSET Trial Summary
This trial found that combining sacituzumab govitecan with alpelisib may help treat HER2-negative breast cancer that has spread or returned.
ASSET Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowASSET Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ASSET Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My calcium levels are normal or slightly above but not concerning.I have a GI condition that could affect how I absorb medication.I had palliative radiation therapy less than 2 weeks ago or still have side effects from it.My brain metastases are stable, I'm not on steroids or specific seizure meds, and it's been over 21 days since their treatment.I have lung inflammation or scarring.I am on a medication that affects my heart's rhythm and cannot change it.Your absolute neutrophil count (a type of white blood cell) is at least 1500 per microliter. If you have a condition causing low neutrophil count, you may still be eligible if your count is between 1000-1500 and your doctor thinks the trial treatment won't increase your risk of infection too much.I have inflammatory breast cancer.Women who could become pregnant must have a negative pregnancy test within 24 hours before starting treatment.Your potassium levels are within the normal range at the hospital where you're being treated.I haven't had cancer, except for certain skin or cervical cancers, in the last 3 years.Your HbA1c level is less than or equal to 6.4%.I have had pancreatitis within the last year or have chronic pancreatitis.I've had chemotherapy, hormonal therapy, and anti-PD-1/PD-L1 therapy if suitable.I have a heart rhythm problem.My bilirubin levels are within the normal range or slightly higher if I have liver metastases.Your magnesium levels are within the normal range at the hospital.I do not have an active Hepatitis B or C infection.I have a history of heart problems.I am 18 years old or older.My liver disease is moderately to severely advanced.I stopped taking BCRP inhibitors at least a week ago.I, or my legal representative, can understand the study and agree to sign the consent form.My breast cancer is HER2-negative, advanced, and cannot be cured with surgery.I finished my last chemotherapy for breast cancer more than 2 weeks ago and have mostly recovered from its side effects.My hemoglobin level is above 9 g/dL, possibly after a transfusion.My kidneys work well enough to clear at least 35 mL/min of creatinine.I have untreated brain symptoms.I am currently taking warfarin or a similar blood thinner.Your blood sugar levels when you have not eaten should be less than 140 mg/dL or 7.8 mmol/L.I am able to get out of my bed or chair and move around.I had radiation for bone metastases and it's been over 2 weeks since my last treatment.I have type I diabetes or my type II diabetes is not under control.Your blood amylase levels are not more than twice the normal limit.You have been diagnosed with HIV in the past. Testing for HIV is not required to participate.Your albumin level in your blood is at least 2.5 grams per deciliter.I have been treated with a PI3K or AKT inhibitor before.My kidney function, measured by creatinine, is within normal limits.I am not currently on strong drugs that affect liver enzymes.I have ongoing jawbone issues not yet healed.My cancer can be measured or seen on tests.I can swallow and keep down pills.I haven't had major surgery in the last 2 weeks or still have major side effects from it.I am not allergic to the study drug and have not had a severe infection in the last 2 weeks.I've taken high-dose steroids recently or am still experiencing their side effects.I am not using, nor do I plan to use, other cancer treatments or experimental drugs during this study.I have had multiple treatments for my cancer that has spread.You have had serious skin reactions like Steven-Johnson Syndrome, erythema multiforme, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic syndrome in the past.I have been treated with sacituzumab govitecan or alpelisib before.My breast cancer is HER2-negative, possibly hormone receptor-positive or triple-negative.Your liver enzyme levels are not too high, unless you have cancer that has spread to your liver.My platelet count is at least 100,000/uL without recent transfusions.Your blood test for lipase is within the normal range for the hospital where you are being treated.
- Group 1: Dose level 1: alpelisib 250 mg plus sacituzumab govitecan 8 mg/kg
- Group 2: Dose level 2: alpelisib 250 mg plus sacituzumab govitecan 10 mg/kg
- Group 3: Dose level 3: alpelisib 300 mg plus sacituzumab govitecan 10 mg/kg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Sacituzumab govitecan a secure option for those in need of treatment?
"With limited clinical evidence to support safety and efficacy, Sacituzumab govitecan was rated a 1 on the risk spectrum."
What is the current sample size of this research endeavor?
"Affirmative. The clinicaltrial.gov website reveals that this experiment, initiated on March 28th 2022, is presently recruiting individuals. Around 18 volunteers are required from 7 distinct sites."
What medical maladies is Sacituzumab govitecan usually prescribed to address?
"Sacituzumab govitecan is used to facilitate therapeutic processes, as well as to medicate certain conditions such as pharmacotherapy, uc 84572, and breast cancer."
How many medical institutions are conducting this experiment?
"Currently, this trial is occurring in 7 different sites. Specifically, Kansas City, Lee's Summit and Westwood have clinical locations; other centres are also available for recruitment. To reduce travel burdens for those participating in the study it may be wise to choose a clinic nearest you."
Has Sacituzumab govitecan been tested in any prior scientific experiments?
"Presently, 64 Sacituzumab govitecan related studies are actively being conducted with 12 in the third phase. While many of these trials are New york-based, over two thousand six hundred and ninety five sites worldwide have research projects revolving around Sacituzumab govitecan."
Is there still an opportunity for potential subjects to join this investigation?
"Per current information on clinicaltrials.gov, this medical test is actively recruiting volunteers to participate. It was first announced on March 28th 2022 and underwent its most recent update April 4th 2022."
Share this study with friends
Copy Link
Messenger